4121 The beneficial, anti-fibrotic effects of chemokine receptor 2 and 5 antagonists on fat-exposed mouse primary hepatic stellate cells (pHSCs)
OBJECTIVES/GOALS: Non-alcoholic steatohepatitis (NASH) is a leading cause of cirrhosis in the world for which no anti-fibrotic therapies exist. We hypothesized that BMS-22 and maraviroc (MVC), chemokine receptor 2 (CCR2) and 5 (CCR5) antagonists, respectively, would diminish the fibrogenic activity...
Enregistré dans:
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Cambridge University Press
2020-06-01
|
| Collection: | Journal of Clinical and Translational Science |
| Accès en ligne: | https://www.cambridge.org/core/product/identifier/S2059866120003179/type/journal_article |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|